Ultrasound therapy developer Theraclion is highlighting research results from a study showing long-term effectiveness and safety of its Echopulse system for the treatment of breast fibroadenoma.
The research, published in January in the Journal of Therapeutic Ultrasound, included 51 women with breast fibroadenoma from four centers in Bulgaria and France. The study found that breast fibroadenoma volume was reduced by a mean of 59% six months after women had undergone the echotherapy treatment, and a mean of 72.5% after 12 months (J Ther Ultrasound, 22 January 2015).
Pain related to the breast fibroadenoma improved until it was completely resolved, and no serious side effects were reported, the company said.
